Hansa Biopharma’s Idefrix leads to one-year GvHD survival in kidney transplant

Hansa Biopharma’s Idefrix (imlifidase) has seen a 90% one-year survival from GvHD in patients following a kidney transplant. Hansa will apply to the EMA to convert Idefrix’s conditional approval into full marketing authorisation. Hansa was told to conduct the post-marketing study by the EMA. Credit: SewcreamStudio Creative / iStock via Getty Images. Hansa Biopharma’s Idefrix (imlifidase) has seen a 90% one-year survival from graft versus host disease (GvHD) in patients following a kidney transplant, supporting full approval. The open-label, European 20-HMedIdeS-19 post-authorisation efficacy study (PAES) (NCT05369975) investigated one-year graft failure-free survival and patient survival in highly sensitised patients who have…

Source: Clinical Trials Arena